Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 25 or more amino acid residues in defined sequence
Reexamination Certificate
2007-03-27
2007-03-27
Tate, Christopher R. (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
25 or more amino acid residues in defined sequence
C530S300000, C514S002600, C514S012200, C424S001690
Reexamination Certificate
active
11031488
ABSTRACT:
The invention provides inhibitors of matrix metalloproteinases that are useful for encouraging the development of healthy skin and for treating wounds. The inhibitors are peptides having sequences related to cleavage regions of the proenzyme forms of matrix metalloproteinases. The peptide inhibitors of the invention can be formulated into therapeutic compositions, lotions, creams, skin covering and wound dressings that facilitate healing and healthy skin development, discourage scarring and wrinkling and ameliorate the effects of healing.
REFERENCES:
patent: 4424552 (1984-01-01), Saint Marcoux
patent: 5270447 (1993-12-01), Liotta et al.
patent: 5280106 (1994-01-01), Liotta et al.
patent: 5372809 (1994-12-01), Liotta et al.
patent: 5585356 (1996-12-01), Liotta et al.
patent: 5698671 (1997-12-01), Stetler-Stevenson et al.
patent: 5770691 (1998-06-01), Fields et al.
patent: 5811252 (1998-09-01), Verheijen
patent: 5869277 (1999-02-01), Stetler-Stevenson et al.
patent: 6043087 (2000-03-01), Bini et al.
patent: 6127139 (2000-10-01), Te Koppele et al.
patent: 6184022 (2001-02-01), Seiki et al.
patent: 6191225 (2001-02-01), Barkac et al.
patent: 6204043 (2001-03-01), Shapiro
patent: H1973 (2001-07-01), Hu
patent: 6274703 (2001-08-01), Goldberg
patent: 6399371 (2002-06-01), Falduto et al.
patent: 6482802 (2002-11-01), Hu et al.
patent: 6812339 (2004-11-01), Venter et al.
patent: 6906036 (2005-06-01), Quirk et al.
patent: 2001/0016333 (2001-08-01), Seiki et al.
patent: 2001/0031478 (2001-10-01), Bronstein et al.
patent: 2003/0012794 (2003-01-01), Srivastava et al.
patent: 2003/0096757 (2003-05-01), Quirk et al.
patent: 2003/0166567 (2003-09-01), Quirk et al.
patent: 2003/0199440 (2003-10-01), Dack et al.
patent: 2004/0010001 (2004-01-01), Au et al.
patent: 2004/0259802 (2004-12-01), Yang et al.
patent: 0917165 (1999-05-01), None
patent: 06213888 (1994-05-01), None
patent: 06300757 (1994-10-01), None
patent: 07159402 (1995-06-01), None
patent: 08134098 (1996-05-01), None
patent: 08136548 (1996-05-01), None
patent: 08217800 (1996-08-01), None
patent: 09023889 (1997-01-01), None
patent: 09084589 (1997-03-01), None
patent: 09087299 (1997-03-01), None
patent: 09136841 (1997-05-01), None
patent: 09206099 (1997-08-01), None
patent: 09249700 (1997-09-01), None
patent: 10287700 (1997-09-01), None
patent: 10210982 (1998-08-01), None
patent: 10313896 (1998-12-01), None
patent: 2000270874 (2000-10-01), None
patent: 2001011093 (2001-01-01), None
patent: WO-90/10228 (1990-09-01), None
patent: WO 94/10208 (1994-05-01), None
patent: WO 96/18725 (1997-06-01), None
patent: WO-97/25437 (1997-07-01), None
patent: WO 98/04287 (1998-02-01), None
patent: WO-98/12309 (1998-03-01), None
patent: WO-98/31818 (1998-07-01), None
patent: WO-98/34641 (1998-08-01), None
patent: WO-98/40475 (1998-09-01), None
patent: WO-98/42865 (1998-10-01), None
patent: WO-99/05261 (1999-02-01), None
patent: WO-99/31969 (1999-07-01), None
patent: WO-99/58126 (1999-11-01), None
patent: WO-99/65519 (1999-12-01), None
patent: WO-00/20860 (2000-04-01), None
patent: WO-00/63227 (2000-10-01), None
patent: WO-00-74634 (2000-12-01), None
patent: WO-01/10437 (2001-02-01), None
patent: WO-01/38558 (2001-05-01), None
patent: WO-01/62206 (2001-08-01), None
patent: WO-01/62261 (2001-08-01), None
patent: WO-03/018748 (2003-03-01), None
Agren, M. S., “Matrix Metalloproteinases (MMPs) are Required for Re-Epitheliazation of Cutaneous Wounds”,Archives Dermatol. Res.,291, (1999),583-590.
Attie, K.M., “Genetic Studies in Idiopathic Short Stature”,Current Opinion in Pediatrics,12, (2000),400-404.
Azzam, H. S., et al., “Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production”,J. Natl. Cancer Inst.,85 (21), (Nov. 3, 1993),1758-1764.
Baker, E. A., et al., “Proteinases, their inhibitors, and cytokine profiles in acute wound fluid”,Wound Repair Regen.,8 (5), (2000),392-398.
Becker, J. W., et al., “Stromelysin-1: Three-Dimensional Structure of the Inhibited Catalytic Domain and of the C-Truncated Proenzyme”,Protein Science,4(10), (Oct. 1995),1966-1976.
Berend, K. R., et al., “Association Between Ratio of Matrix Metalloproteinase-1 to Tissue Inhibitor of Metalloproteinase-1 and Local Recurrence, Metastasis, and Survival in Human Chondrosarcoma”,Journal of Bone&Joint Surgery—Americanvol. 80(1), (1999),893-895.
Bhide, V. M., et al., “Use of a fluorogenic septapeptide matrix metalloproteinase assay to assess responses to periodontal treatment”,J. Periodontol.,71(5), (2000),690-700.
Bickett, D. M., et al., “A high throughput fluorogenic substrate for interstitial collagenase (MMP-1) and gelatinase (MMP-9)”,Anal. Biochem.,212 (1), (Jul. 1993),58-64.
Bickett, D. M., et al., “A high throughput fluorogenic substrate for stromelysin (MMP-3)”,Ann. N Y Acad. Sci.,732, (1994),351-355.
Blaschke, R. J., et al., “SHOX:Growth, Léri-Weill and Turner Syndromes”,TEM, 11, (2000),227-230.
Bremer, C., et al., “In Vivo molecular toarget assessment or matrix metaloproteinase inhibition”,Nat. Med.,7 (6), (2001),743-748.
Brown, P. D., “Cellular activation of the 72 kDa type IV pro collagenase/TIMP-2 complex”,13-Mammalion Biochem,119, (1993),p. 573.
Brown, P. D., et al., “Cellular activation of the 72 kDa type IV procollagenase/TIMP-2 complex”,Kidney Int.,43 (1), (1993),163-170.
Brown, R. L., et al., “PDGF and TGF-aAct Synergistically to Improve Wound Healing in the Genetically Diabetic Mouse”,Journal of Surgical Research,56, (1994),562-570.
Browner, M. F., “Matrilysin-Inhibitor Complexes: Common Themes among Metalloproteases”,Biochemistry,34, (1995),6602-6610.
Cabrele, C., et al., “Y-Receptor Affinity Modulation by the Design of Pancreatic Polypeptide/Neuropeptide Chimera Led to Y5-Receptor Ligands With Picomolar Affinity”,Peptides,22, (2001),365-378.
Calabrese, E. J., “Cell Migration / Chemotaxis: Biphasic Dose Responses”,Critical Reviews in Toxicology,31 (4&5), (2001),615-624.
Calvin, M., “Cutaneous Wound Repair”,Wounds: A Compendium of Clinical Research and Practice,10 (1), (1998),12-32.
Chen, L. C., et al., “Disruption of the cysteine-75 and zinc ion coordination is not sufficient to activate the precursor of human matrix metalloproteinase 3 (stromelysin 1)”,Biochemistry,32 (39), (1993),10289-10295.
Chi, Yeon Sook , et al., “Effects of the Chestnut Inner Shell Extract on the Expression of Adhesion Molecules, Fibronectin and Vitronectin, of Skin Fibroblasts in Culture”,Archive of Pharmacal Research,25 (4), (2002),469-474.
Chin, Jason W., et al., “Concerted Evolution of Structureand Function in a Miniature Protein”,J. Am. Chem. Soc.,123, (2001),2929-2930.
Chin, Jason W., et al., “Methodology for Optimizing Functional Miniature Proteins Based on Avian Pancreatic Polypeptide Using Phage Display”,Bioorganic&Medicinal Chemistry Letters,1, (2001),1501-1505.
Clark, R. A., “Wound Repair”,The Molecular and Cellular Bilogy of Wound Repair—2nd ed., Plenum Press, NY,(1995),3-50.
Colandrea, T. D., “Epidermal Expression of Collagenase Delays Wound-Healing in Transgenic Mice”,The Journal of Investigative Dermatology,(1998),1029-1033.
Coppola, G., et al., “Effect of Intraperitoneally, Intravenously and Intralesionally Administered Monoclonal Anti-β-FGF Antibodies on Rat Chondrosarcoma Tumour Vascularization and Growth”,Anticancer Research,17(3C), (1997),2033-2040.
Dailey, L., et al., “A Network of Transcriptional and Signaling Events is Activated by FGF to Induce Chondrocyte Growth Arrest and Differentiation”,The Journal of Cell Biology,161(6), (2003),1053-1066.
Duivenvoorden, W. C., “Use of Tetracycline as an Inhibitor of Matrix Metalloproteinase Activity Secreted by Human Bone-Metastasizing Cancer Cells”,Inv
Malik Sohail
Quirk Stephen
Audet Maury
Kimberly--Clark Worldwide, Inc.
Schwegman Lundberg Woessner & Kluth P.A.
Tate Christopher R.
LandOfFree
Anti-aging and wound healing compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-aging and wound healing compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-aging and wound healing compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3788090